Cambrian Biopharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic
02-Nov-2021 -
Cambrian Biopharma, a multi-asset longevity biotech, announced the close of an oversubscribed Series C financing, which raised $100 million. The financing was co-led by Anthos Capital and SALT Fund, with participation from existing investors Apeiron Investment Group, Future Ventures, Moore ...
age-related diseases
drug discovery
longevity
+1